Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ARO-APOC3 in adults with familial chylomicronemia syndrome
jRCT2031220249Phase 3Active, not recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Aug 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
A Phase 3 trial of plozasiran in primary chylomicronemia (FCS), sponsored by Arrowhead Pharmaceuticals. Started Aug 2022; status: active, not recruiting.
02
Drugs
plozasiran
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on jRCT2031220249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220249.